The Drug Enforcement Administration (DEA) Philadelphia Division’s Intelligence Program (PDIP) reviewed a set of data indicators for the years 2015-2018 to assess the current prescription opioid threat in Pennsylvania. Analysis revealed that a positive change in the prescription opioid threat may be underway...
The DEA Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. The data in this report is from 2016.
Crafting initiatives and strategies to address opioid supply, demand, and misuse requires timely and actionable information and data, which this report endeavors to provide. This report presents a comprehensive assessment of the opioid crisis in Pennsylvania, through collection and analysis of supply and demand indicators and intelligence, as well as detailed county level analysis of multiple opioid misuse data sources.
The Drug Enforcement Administration’s Heroin Signature Program (HSP) analyzed several hundred wholesale-level heroin samples in 2016 to identify the geographic area where the samples were manufactured (Mexico, South America [SA], Southwest Asia [SWA], or Southeast Asia [SEA]).
The purpose of the Greater New Orleans Situational Drug Report is to identify current and emerging drug trends within the New Orleans metropolitan area as well as to deliver accurate and timely strategic intelligence to assist drug treatment and prevention organizations in the development of drug prevention and mitigation strategies. This assessment provides an overview of the region’s primary drug threats.
The 2018 National Drug Threat Assessment (NDTA) is a comprehensive strategic assessment of the threat posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs. The report combines federal, state, local, and tribal law enforcement reporting; public health data; open source reporting; and intelligence from other government agencies to determine which substances and criminal organizations represent the greatest threat to the United States.
This Drug Enforcement Administration (DEA) Intelligence Report contains new and updated information on slang terms and code words from a variety of law enforcement and open sources, and serves as an updated version to the product entitled “Drug Slang Code Words” published by the DEA in May 2017. It is designed as a ready reference for law enforcement personnel who are confronted with hundreds of slang terms and code words used to identify a wide variety of controlled substances, designer drugs, synthetic compounds, measurements, locations, weapons, and other miscellaneous terms relevant to the drug trade. Although every effort was made to ensure the accuracy and completeness of the information presented, due to the dynamics of the ever-changing drug scene, subsequent additions, deletions, and corrections are inevitable. Future addendums and updates to this report will attempt to capture changed terminology to the furthest extent possible. This compendium of slang terms and code words is alphabetically ordered, with new additions presented in italic text, and identifies drugs and drug categories in English and foreign language derivations.
The Drug Enforcement Administration (DEA) New Jersey Division’s Intelligence Program conducted a bi-annual assessment of the drug threats occurring within the State of New Jersey between January and June 2017. This report highlights the strategic and significant findings regarding the illicit drug trends in the New Jersey Division’s (NJD) area of responsibility (AOR). Unless otherwise noted, data and findings are from DEA reporting.
Fentanyl is the most prevalent and the most significant synthetic opioida threat to the United States and will very likely remain the most prevalent synthetic opioid threat in the near term. The fentanyl threat remains most severe in the white powder heroin user market in the Midwest and Northeast United States, and fentanyl availability continues to be primarily by itself or with heroin. Fentanyl mixtures with non-opioid substances are a cause for public health concern due to the high potential for large numbers of fatal overdoses in short periods of time; however, there is no evidence that transnational criminal organizations (TCO) are trafficking strategic quantities of fentanyl already mixed with non-opioid drugs. Fentanyl’s popularity is unlikely to be challenged in the near term, but traffickers will likely continue to produce new fentanyl-related substances and other novel opioids.
In June and July 2017, law enforcement authorities made multiple undercover purchases of crack cocaine from one dealer in Baltimore, MD. In September 2017, official laboratory results indicated that two of these purchases tested as N-ethylpentylone Hydrochloride, a synthetic cathinone (“bath salts”) derivative classified as a Schedule I Controlled Substance Analogue.
As of October 2017, a review of Drug Enforcement Administration (DEA) National Forensic Laboratory Information System (NFLIS) data show that cocaine submissions indicate it is the number one seized substance by incident by law enforcement officials in South Carolina. The number of submissions has fluctuated with a high of 4,764 (in 2010) and a low of 3,492 (in 2012). The percent of cocaine submissions has declined every year since 2011 when compared to all South Carolina submissions.
The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted an assessment of laboratory-analyzed drug seizures. Some seized cocaine exhibits were found to contain cocaine and fentanyl, as well as a combined cocaine and fentanyl presence in overdose death toxicology reporting. This analysis was conducted in response to reported increases in the co-occurrence of cocaine and fentanyl in other regions and subsequent inquiries regarding trends in Pennsylvania.
The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted a review of laboratory-analyzed drug seizures for the Commonwealth of Pennsylvania. The resulting analysis of this data formed the basis for estimating the level of drug presence in Pennsylvania and highlighted trends in drug availability between 1999 and 2016.
The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) Intelligence Program maintains situational awareness of drug availability, abuse, trafficking patterns, adulterants, concealment methods, etc., through analysis of law enforcement and public health information and data, as well as law enforcement source information.
A review of cocaine exhibits acquired by law enforcement authorities during operations across Florida and analyzed by forensic laboratories during the period from 2016 to 2017 revealed the widespread adulteration of cocaine with fentanyl and fentanyl-related substances. Fentanyl, a Schedule II opioid analgesic approximately 50 times more potent than heroin and 100 times more potent than morphine, carries a high risk of overdose and can be lethal at the 2-milligram range. Forensic chemists discovered fentanyl and fentanyl-related substances including acetyl fentanyl, carfentanil, Furanylfentanyl, and p-fluoroisobutyryl fentanyl in over 180 cocaine exhibits. Carfentanil, a synthetic opioid that is approximately 10,000 times more potent than morphine, was the most prevalent of the fentanyl-related substances found in Florida’s cocaine seizures.
The Domestic Methamphetamine Threat Assessment provides a comprehensive strategic assessment of the threat posed to the United States by the trafficking and use of methamphetamine.
This report combines federal, state, and local law enforcement reporting; public health data; news reports; and intelligence from other government agencies to assess the methamphetamine threat to the United States.
Methamphetamine is a Schedule II stimulant under the Controlled Substances Act (CSA). Methamphetamine is a synthetically-produced central nervous system stimulant that metabolizes slowly and has long-lasting effects.
The abuse of drugs containing fentanyl is killing Americans. Misinformation and inconsistent recommendations regarding fentanyl have resulted in confusion in the first responder community. This document provides scientific, evidence-based recommendations to protect first responders from exposure.
The Drug Enforcement Administration’s (DEA) Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin, along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. In 2015, a total of 823 qualified exhibits were purchased. Of those exhibits, 600 were classified as Mexican-origin heroin (267 Mexican-South American [MEX-SA], 252 Mexican-Black Tar [MEX/T], 49 Mexican-Brown Powder [MEX/BP], and 32 Mexican [MEX]); 178 heroin exhibits were classified as Inconclusive Origin-South American Processing Method (INC-SA); 42 were classified as South American (SA) heroin; and 3 were classified as Southwest Asian (SWA) heroin. During 2015, for the tenth consecutive year, no Southeast Asian (SEA) heroin exhibits were purchased through the HDMP.
The 2017 National Drug Threat Assessment (NDTA)1 is a comprehensive strategic assessment of the threat posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs. The report combines federal, state, local and tribal law enforcement reporting; public health data; open source reporting; and intelligence from other government agencies to determine which substances and criminal organizations represent the greatest threat to the United States.
Over the past 10 years, the drug landscape in the United States has shifted, with the opioid threat (controlled prescription drugs, synthetic opioids, and heroin) reaching epidemic levels, impacting significant portions of the United States. While the current opioid crisis has deservedly garnered significant attention, the methamphetamine threat has remained prevalent; the cocaine threat appears to be rebounding; new psychoactive substances (NPS) continue to be a challenge; and the focus of marijuana enforcement efforts continues to evolve. Drug poisoning deaths are the leading cause of injury death in the United States; they are currently at their highest ever recorded level and, every year since 2011, have outnumbered deaths by firearms, motor vehicle crashes, suicide and homicide. In 2015, approximately 140 people died every day from drug poisoning (see Figure 1).
The Drug Enforcement Administration’s (DEA) Heroin Signature Program (HSP) analyzes several hundred wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.